DBVTF News and Press, Dbv Techs Boulogne Bill From 01/04/23

Monthly information regarding the total number of voting rights and total number of shares of the Company as of Dec em ber 3 1 , 202 2 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Mark...

DBV Technologies S.A. (DBVT) Q3 2022 Earnings Conference Call November 04, 2022 5:00 PM ET Company Participants Anne Pollak – Investor Relations Daniel Tassé – Chief Executive Officer Pharis Mohideen – Chief Medical Officer Confere...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

Summary Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +116.8% YTD. This week two picks beat 10% gains in less than week with peak gains in BKKT +14.5% and CXM +12.5% with RIOT peaking ...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

DBV Technologies (NASDAQ:DBVT) is planning to raise $194M in gross proceeds via a private investment in public equity (PIPE) financing. The company intends to sell ~32.86M ordinary shares, and pre-funded warrants to buy up to ~28.28M shares. The company said the ordinary shares will be sold a...

DBV Technologies S.A. (DBVT) Q1 2022 Results Conference Call May 02, 2022 05:00 PM ET Company Participants Anne Pollak - Head, IR Daniel Tassé - CEO Conference Call Participants Jon Wolleben - JMP Securities Presentation Operator Welcome to the DBV Technologies First Quarter 2022 Earning...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

DBV Technologies S.A. (DBVT) Q4 2021 Earnings Conference Call March 03, 2022 05:00 PM ET Company Participants Anne Pollak - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer Pharis Mohideen - Chief Medical Officer Confer...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...